LIDE is an award winning oncology contract research organization with 12 years of delivering preclinical drug evaluation services to over 200+ clients worldwide. LIDE offers traditional CRO services and has a collection of more than 1900 patient derived xenograft (PDX) models covering 50+ cancer types, of which 200+ are special drug resistant and/or genetically altered. LIDE’s proprietary MiniPDX and IO-FIVE tools offer an evolved approach to drug r&d that maximizes budget efficiency and minimizes time to validation.

LIDE differentiates itself from other CROs by continually conducting self-funded internal research of its immense tumor bio bank, and working with KOLs in the academic space to vigorously promote the development and application of translational medical research. We also adopt the highest international operational standards. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.